Osaic Holdings
GALT icon

Osaic Holdings’s Galectin Therapeutics GALT Stock Holding History

Osaic Holdings’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.59M Buy
1,203,725
+81,055
+7% +$210K 0.01% 1447
2026
Q1 		$3.13M Buy
1,122,670
+32,080
+3% +$97.6K ﹤0.01% 1707
2025
Q4 		$4.54M Sell
1,090,590
-134,134
-11% -$706K 0.01% 1442
2025
Q3 		$5.24M Sell
1,224,724
-40,660
-3% -$153K 0.01% 1441
2025
Q2 		$2.67M Buy
1,265,384
+41,968
+3% +$62.8K ﹤0.01% 1677
2025
Q1 		$1.49M Buy
1,223,416
+42,881
+4% +$60.2K ﹤0.01% 1898
2024
Q4 		$1.52M Sell
1,180,535
-1,560
-0.1% -$3.74K ﹤0.01% 1872
2024
Q3 		$3.25M Buy
1,182,095
+56,100
+5% +$138K 0.01% 1346
2024
Q2 		$2.54M Sell
1,125,995
-138,850
-11% -$422K 0.01% 1448
2024
Q1 		$3.02M Buy
1,264,845
+13,797
+1% +$26.1K 0.01% 1392
2023
Q4 		$2.08M Sell
1,251,048
-2,024,144
-62% -$3.93M ﹤0.01% 1830
2023
Q3 		$6.29M Buy
3,275,192
+1,839,635
+128% +$3.03M 0.01% 1161
2023
Q2 		$2.07M Buy
1,435,557
+163,797
+13% +$278K ﹤0.01% 1840
2023
Q1 		$2.67M Buy
1,271,760
+1,432
+0.1% +$2.31K 0.01% 1600
2022
Q4 		$1.44M Sell
1,270,328
-31,794
-2% -$42.4K ﹤0.01% 2022
2022
Q3 		$2.12M Buy
1,302,122
+17,641
+1% +$33K ﹤0.01% 1591
2022
Q2 		$1.68M Buy
1,284,481
+18,661
+1% +$26.8K ﹤0.01% 1793
2022
Q1 		$2.04M Buy
1,265,820
+18,419
+1% +$35.6K ﹤0.01% 1904
2021
Q4 		$2.58M Sell
1,247,401
-26,556
-2% -$75.8K ﹤0.01% 1556
2021
Q3 		$4.94M Buy
1,273,957
+800
+0.1% +$2.71K 0.01% 1066
2021
Q2 		$4.07M Buy
1,273,157
+51,173
+4% +$182K 0.01% 1165
2021
Q1 		$2.65M Buy
1,221,984
+126,009
+11% +$282K 0.01% 1386
2020
Q4 		$2.45M Buy
1,095,975
+60,154
+6% +$158K 0.01% 1290
2020
Q3 		$2.77M Buy
1,035,821
+23,391
+2% +$65.5K 0.01% 1112
2020
Q2 		$3.1M Buy
1,012,430
+148,155
+17% +$373K 0.01% 972
2020
Q1 		$1.69M Buy
+864,275
New +$2.1M 0.01% 1168

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Osaic Holdings's GALT Position: Q2 2026 in Review

Osaic Holdings increased its Galectin Therapeutics (GALT) stake by 7.2% in Q2 2026, buying an estimated $210K and bringing the position to 1,203,725 shares worth $5.59M. The position accounts for 0.01% of the portfolio, ranked #1447.

Osaic Holdings first reported a position in GALT in Q1 2020 and has held it in 26 quarters since. The position peaked at $6.29M in Q3 2023. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Osaic Holdings held 1,203,725 shares of Galectin Therapeutics worth $5.59M as of Q2 2026.
  • Osaic Holdings bought 81,055 Galectin Therapeutics shares in Q2 2026, an estimated $210K.
  • Galectin Therapeutics made up 0.01% of Osaic Holdings's portfolio in Q2 2026, its #1447 holding.
  • Osaic Holdings first reported a position in Galectin Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • Osaic Holdings's Galectin Therapeutics position peaked at $6.29M in Q3 2023.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.